吕雅琪，女，博士，讲师。2013年本科毕业于中国药科大学基础药学理科基地班，获理学学士学位；2018年博士毕业于中国药科大学药剂学专业，获药剂学博士学位。2018-2019年在香港城市大学化学系作科研助理研究；2019 -2021年受欧盟玛丽居里行动地平线2020人才计划（Marie Skłodowska-Curie Individual Fellowships）资助，在英国伦敦玛丽女王大学工程与材料科学学院从事科学研究。2021年12月加入上海中医药大学中药学院。主要研究领域包括新型纳米药物递送系统和可注射水凝胶药物递送系统的研究。共在ACS Nano等国际知名学术期刊发表学术论文14篇。
联系方式：ylyu07@shutcm.edu.cn
近5年代表性论文如下：
(1) Yaqi Lv, Chaoran Xu, Xiangmei Zhao, Chenshi Lin, Xin Yang, Xiaofei Xin, Li Zhang, Chao Qin, Xiaopeng Han, Lei Yang, Wei He*, Lifang Yin*. Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells. ACS Nano, 2018, 12(2): 1519-1536.
(2) Yaqi Lv, Xiangmei Zhao, Lidan Zhu, Sijia Li, Qingqing Xiao, Wei He*, Lifang Yin*. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics, 2018, 8(10): 2830-2845.
(3) Yaqi Lyu, Helena Azevedo*. Supramolecular Hydrogels for Protein Delivery in Tissue Engineering. Molecules, 2021, 26(4): 873.
(4) Yaqi Lyu, Qingqing Xiao, Lifang Yin, Lei Yang*, Wei He*. Potent delivery of an MMP inhibitor to the tumor microenvironment with thermosensitive liposomes for the suppression of metastasis and angiogenesis. Signal Transduction and Targeted Therapy, 2019, 4:26.
(5) Yaqi Lyu，Qingqing Xiao, Yi Li, Yubing Wu, Wei He*, Lifang Yin*. “Locked” cancer cells are more sensitive to chemotherapy. Bioengineering & Translational Medicine, 2019, 4(2): e10130.
